secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-223292
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair
--------------------------------------------------------------------------------

- Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.
- Also appointed to Compensation Committee and as chair of newly constituted R&D Committee effective Sept 26.
- Gottesdiener is independent under Nasdaq/SEC rules; no material transactions or family relationships with officers.
- Compensation per standard non-employee director policy plus $12,000 annual retainer for R&D Committee chair.
- Former CEO of Prime Medicine and Rhythm Pharmaceuticals; 16 years at Merck with over 20 drug approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/0001193125-25-223292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/d942032d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-223292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer